Efficacy of the anti-angiogenic approach to solid tumors

Future approaches for treating hematologic disease.

Current pharmaceutical biotechnology·2002

Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.

Biotechnology and bioengineering·2001

Chromosome localization and gene-copy-number quantification of three random integrations in Chinese-hamster ovary cells and their amplified cell lines using fluorescence in situ hybridization.

Biotechnology and applied biochemistry·2001

Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.

Clinical immunology (Orlando, Fla.)·2001

Measurement of protein interaction bioenergetics: application to structural variants of anti-sCD4 antibody.

Methods in enzymology·2000

Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4.

Journal of immunology (Baltimore, Md. : 1950)·2000

Mutant isocitrate dehydrogenase in cancer: Structural biology, small-molecule inhibitors, and future drug discovery strategies.

Drug discovery today·2026

The shelved pipeline: AI can find strategically abandoned medicines and bring them to patients.

Drug discovery today·2026

AI-augmented evidence as the next core competence in rare disease drug development: From snapshots to 360-degree movies.

Drug discovery today·2026

From chemical space to synthetic reality: A framework for makeable-by-design generative AI in drug discovery.

Drug discovery today·2026

From diligence to verification: the emergence of the TechBio-Investor.

Drug discovery today·2026

Rare disease benchmarks: Investment professionals' accuracy and beliefs.

Drug discovery today·2026

Regulatory roles of pyroptosis-associated lncRnas in breast cancer progression and immune microenvironment.

Cell cycle (Georgetown, Tex.)·2026

Insights Into the Mechanisms of Biological Aging That Guide Translational and Clinical Research.

Aging medicine (Milton (N.S.W))·2026

Depletion of Soluble PD-L1 with Engineered Nanoparticles Promotes Antitumor Immunity and Tumor Control.

International journal of nanomedicine·2026

Biomaterial-based Drug delivery strategies for head and neck cancer: Local delivery, combination therapy, and translational challenges.

International journal of pharmaceutics: X·2026

Enhanced anticancer efficacy of Pa-MAP 1.9 peptide-coated silver nanostars on breast cancer cells.

Materials today. Bio·2026

Surface-engineered milk-derived extracellular vesicles enable oral miRNA therapy against immunosuppressive pancreatic cancer.

Materials today. Bio·2026

Related Experiment Videos

Efficacy of the anti-angiogenic approach to solid tumors

Related Concept Videos

Future approaches for treating hematologic disease.

Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.

Chromosome localization and gene-copy-number quantification of three random integrations in Chinese-hamster ovary cells and their amplified cell lines using fluorescence in situ hybridization.

Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.

Measurement of protein interaction bioenergetics: application to structural variants of anti-sCD4 antibody.

Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4.

Mutant isocitrate dehydrogenase in cancer: Structural biology, small-molecule inhibitors, and future drug discovery strategies.

The shelved pipeline: AI can find strategically abandoned medicines and bring them to patients.

AI-augmented evidence as the next core competence in rare disease drug development: From snapshots to 360-degree movies.

From chemical space to synthetic reality: A framework for makeable-by-design generative AI in drug discovery.

From diligence to verification: the emergence of the TechBio-Investor.

Rare disease benchmarks: Investment professionals' accuracy and beliefs.

Regulatory roles of pyroptosis-associated lncRnas in breast cancer progression and immune microenvironment.

Insights Into the Mechanisms of Biological Aging That Guide Translational and Clinical Research.

Depletion of Soluble PD-L1 with Engineered Nanoparticles Promotes Antitumor Immunity and Tumor Control.

Biomaterial-based Drug delivery strategies for head and neck cancer: Local delivery, combination therapy, and translational challenges.

Enhanced anticancer efficacy of Pa-MAP 1.9 peptide-coated silver nanostars on breast cancer cells.

Surface-engineered milk-derived extracellular vesicles enable oral miRNA therapy against immunosuppressive pancreatic cancer.

Related Experiment Videos

Efficacy of the anti-angiogenic approach to solid tumors

Related Concept Videos

Related Articles